Luteal phase characteristics following GnRH antagonist or agonist treatment - a comparative study

被引:24
作者
Friedler, S [1 ]
Gilboa, S [1 ]
Schachter, M [1 ]
Raziel, A [1 ]
Strassburger, D [1 ]
El, RR [1 ]
机构
[1] Tel Aviv Univ, Sakler Sch Med, Assaf Harofeh Med Ctr, IVT & Infertil Unit, Tel Aviv, Israel
关键词
GnRH agonists; GnRH antagonists; luteal phase in IVF;
D O I
10.1016/S1472-6483(10)60976-5
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Due to inherent differences between gonadotrophin-relleasing hormone (GnRH) antagonists and agonists, their late effect on ovarian steroidal production during the luteal phase of IVF cycles may differ. The aim of this study was to characterize and compare the luteal phase hormonal profile after the use of GnRH antagonists or agonists in ovarian stimulation protocols for IVF, in non-conception cycles, to avoid the effect of human chorionic gonadotrophin (HCG) during the luteal phase in conception cycles. Seventy-eight normo-ovulatory patients < 35 years old, undergoing IVF due to male or tubat infertility were randomly allocated either to a GnRH antagonist (study group) or GnRH agonist treatment (control group). Similar standard luteal support was given to all patients, using vaginal micronized progesterone. In non-conception cycles, no statistically significant differences were found comparing luteal phase. oestradiol or progesterone levels in the study and control groups. No statistically significant differences were found comparing the hormonal profile dynamics, the mid-luteal (HCG day +8) oestradiol/progesterone ratio and the percentage of mid-luteal oestradiol decline between the study and control groups. In conclusion, similar characteristics and dynamics of luteal phase oestradiol and progesterone were demonstrated comparing ovarian stimulation for IVF using GnRH agonist or antagonists, under similar luteal support.
引用
收藏
页码:27 / 32
页数:6
相关论文
共 13 条
[1]   The luteal phase of nonsupplemented cycles after ovarian superovulation with human menopausal gonadotropin and the gonadotropin-releasing hormone antagonist Cetvorelix [J].
Albano, C ;
Grimbizis, G ;
Smitz, J ;
Riethmüller-Winzen, H ;
Reissmann, T ;
Van Steirteghem, A ;
Devroey, P .
FERTILITY AND STERILITY, 1998, 70 (02) :357-359
[2]  
ALBANO C, 1999, LUTEAL PHASE CLIN OU, V14, P1426
[3]  
ALBANO C, 2001, INFERTILITY REPROD M, V12, P163
[4]  
ALINANY H, 2002, COCHRANE LIBR ISSUE
[5]   A pilot study involving minimal ovarian stimulation for in vitro fertilization: extending the "follicle-stimulating hormone window" combined with the gonadotropin-releasing hormone antagonist cetrorelix [J].
de Jong, D ;
Macklon, NS ;
Fauser, BCJM .
FERTILITY AND STERILITY, 2000, 73 (05) :1051-1054
[6]   Use of third generation gonadotropin-releasing hormone antagonists in in vitro fertilization-embryo transfer:: A review [J].
Elter, K ;
Nelson, LR .
OBSTETRICAL & GYNECOLOGICAL SURVEY, 2001, 56 (09) :576-588
[7]  
GIBSON M, 1991, FERTIL STERIL, V55, P522
[8]   Embryo implantation: the Rubicon for GnRH antagonists [J].
Hernandez, ER .
HUMAN REPRODUCTION, 2000, 15 (06) :1211-1216
[9]   Is there a difference in the function of granulosa-luteal cells in patients undergoing in-vitro fertilization either with gonadotrophin-releasing hormone agonist or gonadotrophin-releasing hormone antagonist? [J].
Lin, Y ;
Kahn, JA ;
Hillensjö, T .
HUMAN REPRODUCTION, 1999, 14 (04) :885-888
[10]   The use of GnRH antagonists in ovarian stimulation [J].
Olivennes, F ;
Cunha-Filho, JS ;
Fanchin, R ;
Bouchard, P ;
Frydman, R .
HUMAN REPRODUCTION UPDATE, 2002, 8 (03) :279-290